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Abstract. 
Primary bone marrow lymphoma is an extremely rare disease. Its unusual clinical mani-
festations, such as hemophagocytic syndrome, frequently delay correct disease diagnosis, thus 
postponing treatment. Here, we reported a 76-year-old woman presenting with intermittent 
night fever and jaundice for 2 weeks, accompanied with hepatosplenomegaly and pancytopenia. 
Despite antibiotics treatment, the patient’s fever persisted. Computed tomography showed 
hepatosplenomegaly without lymphadenopathy, and bone marrow aspiration and biopsy re-
vealed a large B-cell lymphoma (LBCL) with hemophagocytic lymphohistiocytosis (HLH). 
After chemotherapy with rituximab, cyclophosphamide, vincristine, and prednisolone, both 
jaundice and pancytopenia recovered to normal. After 6 cycles of chemotherapy, the patient 
remained in complete remission for 18 months after diagnosis. Our experience indicates that 
clinicians should consider performing a timely bone marrow examination on patients with un-
known fever and pancytopenia, particularly given that delayed diagnosis of primary bone mar-
row lymphoma can make treatment of this rare disease substantially more challenging. 
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中文摘要 
  原發骨髓淋巴癌是一種罕見的淋巴癌，合併噬血症候群等少見的臨床表現經常延誤
正確即時的診斷和治療。我們報告一名 76 歲女性因間斷發燒、黃疸、肝脾腫大、貧血及
血小板低下兩週前來就診，經給予抗生素後仍持續發燒，全身電腦斷層顯示肝脾腫大，
但無異常淋巴結腫大情形。骨髓檢查確診為大 B 細胞淋巴癌(large B cell lymphoma)併噬血
症候群，經使用標靶併化學治療(rituximab, cyclophosphamide, vincristine, prednisolone)，發
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 燒、黃疸、血球異常等症狀均恢復正常，病患經完成六次化學治療及追蹤十八個月後，
目前疾病仍處於完全緩解狀態。在不明原因發燒合併血球低下的病患，臨床醫師應即時
進行骨髓檢查，並懷疑有原發骨髓淋巴癌之可能。 
 
關鍵字: 原發骨髓大 B 細胞淋巴癌、原發骨髓淋巴癌、非何杰金氏淋巴癌、噬血症
候群、噬血淋巴組織球增生症 
INTRODUCTION 
Large B-cell lymphoma (LBCL) is the most 
common subtype of non-Hodgkin’s lymphoma in 
adults, and several LBCL variants had been defined in 
the World Health Organization classification system 
[1]. The involvement of bone marrow in LBCL usual-
ly indicates systemic dissemination of lymphoma. 
However, several recent reports have defined a dis-
tinctive entity of primary bone marrow LBCL, where 
lymphoma cells primarily involve bone marrow rather 
than lymph nodes [2-9]. The inclusion criteria used in 
each study differ. Consequently, without uniform or 
similar criteria, it is difficult to understand the exact 
incidence, clinical presentation, optimal treatment, and 
prognosis of primary bone marrow LBCL. In the case 
series of Chang et al., primary bone marrow LBCL 
accounted for 1.23% of non-Hodgkin’s lymphoma, 
and 2.65% of diffuse LBCL [6]. Most case series re-
port that this subtype of LBCL usually presents with 
aggressive disease pattern. Nearly all patients are 
treated with chemotherapy regimen against aggressive 
B-cell lymphoma, but the overall outcome is poor [2-4, 
6-9]. Here, we report a patient with primary bone 
marrow LBCL presenting with hemophagocytic lym-
phohistiocytosis. 
 
CASE REPORT 
A 76-year-old woman presented to the emergency 
room (ER) with symptoms of intermittent night fever, 
general weakness, progressive jaundice, tea-colored 
urine, and epigastric discomfort of 2 weeks duration. 
The patient had no history of medical illness, and her 
travel and contact history were also unremarkable. 
On arriving in the ER, the patient was bedridden, 
febrile with body temperature 38°C, tachycardic with 
a pulse rate of approximately 100 beats per minute, 
and tachypnic with a respiratory rate of 20 breaths per 
minute. Blood pressure and oxygenation were both 
normal. Physical examination revealed icteric sclera, 
pale conjunctiva, and vague tenderness upon knocking 
over the right upper quadrant (RUQ) of the abdomen. 
The patient’s liver and spleen were both enlarged, 
with border palpable 2 finger spans below the costal 
margin. There were no palpable lymph nodes in the 
neck, axillary, and inguinal areas.  
The total and direct serum bilirubin levels were 
3.0 and 2.3 mg/dL, respectively. Besides direct hyper-
bilirubinemia, laboratory tests also showed elevated 
alkaline phosphatase (467 U/L), γ-glutamyl transpep-
tidase (98 U/L), and lactic dehydrogenase (533 U/L). 
Both alanine and aspartate aminotransferase were not 
elevated. A routine hemogram revealed normal white 
blood cell (WBC) count with left shifting (WBC 6.7 
K/μL, segment neutrophil 84%, band form neutrophil 
2%), normocytic anemia (hemoglobin 6.2 g/dL, MCV 
85 fL), and thrombocytopenia (platelet 79 K/μL). No 
fragmented or nucleated red blood cells were observed 
in the blood smear. Whole body computed tomogra-
phy showed hepatosplenomegaly without lymphade-
nopathy. The patient was initially managed as a case 
of biliary tract infection based on her fever, RUQ ab-
dominal knocking tenderness, and jaundice. Despite  
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Figure 1. Smear of bone marrow aspiration. (A) Large size bizarre cells with large nucleus with several prominent 
nucleoli (arrows). (B) Hemophagocytosis with several band-from neutrophils being engulfed by histio-
cytes (fat arrows) (A&B: Liu’s stain, 1000X) 
 
 
antibiotics use for 5 days, the patient’s fever persisted 
with progressively worsening direct hyperbiliru-
binemia, cytopenias, lactic acidosis, and deterioration 
of consciousness. Levels of fasting triglyceride, fi-
brinogen, and ferritin were 310 mg/dL, 4.28 g/dL, and 
4670 μg/L, respectively. 
Bone marrow aspiration revealed infiltration of 
abnormal large lymphoid cells (Figure 1A) and evi-
dent histiocytic hemophagocytosis (Figure 1B). Bone 
marrow biopsy showed patchy infiltrate of large lym-
phoma cells (Figure 2A, 2B), which were positive for 
CD20, bcl-6, MUM-1 and negative for CD3, CD5, 
cyclin-D1, CD10, and bcl-2 immunohistochemically 
(Figure 2C, 2D). No lymphoma cells were observed in 
the sinusoids. In situ hybridization for Epstein-Barr 
virus-encoded small RNA (EBER) was negative. 
Arising from the findings of bone marrow pathology 
and whole body CT, the diagnosis of primary bone 
marrow large B-cell lymphoma, non-germinal center 
(non-GC) type was made. 
Considering her age and performance status, 
chemotherapy with R-COP regimen, consisting of 
rituximab 375 mg/m2 day 1, cyclophosphamide 750 
mg/m2 day 1, vincristine (Oncovin) 1.4 mg/m2 day 1, 
and prednisolone 100 mg/day days 1~5, was initiated 
right after the diagnosis was confirmed. The patient’s 
fever subsided on the second day after chemotherapy 
started, and improvements were observed in follow-up 
hemogram, bilirubin, and lactate level. Thereafter, she 
regained clear consciousness on the fifth day of 
chemotherapy. Overall, the patient had received 6 cy-
cles of R-COP chemotherapy, and remained in com-
plete remission 18 months after diagnosis. 
 
DISCUSSION 
We reported a case of primary bone marrow LBCL, 
presenting with hemophagocytic lymphohistiocytosis 
(HLH) with no lymph node involvement. There are 
differences between the criteria used in reported case 
series of primary bone marrow LBCL. Some include 
LBCL with isolated bone marrow involvement, some 
include LBCL without lymphadenopathy, and others 
include LBCL with bone marrow involvement as the 
first manifestation [3-4,7-9]. The presentation of this 
patient was LBCL with bone marrow involvement but 
without lymph node involvement, which fulfilled the 
criteria applied in most series of primary bone marrow 
lymphoma, and was also compatible with the “bone 
marrow-liver-spleen (BLS) type LBCL”, which was 
defined by Yeh et al. as lymphoma limited entirely to  
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Figure 2. Pathological findings of bone marrow biopsy. (A) Patchy infiltration of tumor cells in bone marrow 
[haematoxylin and eosin (H&E), 100X]. (B) Tumor cells are large with several prominent nucleoli. No 
intravascular involvement of tumor cells is found (H&E, 400X). (C) Immunohistochemically, the tu-
mor cells are positive for CD20 (left), and negative for CD10 (right) (200X). (D) Tumor cells are addi-
tionally positive for bcl-6 (left) and MUM-1 (right) (200X), imparting an activated B-cell phenotype 
 
 
the bone marrow, liver and/or spleen without any 
lymph node involvement [2]. Common initial presen-
tations include fever, fatigue, anorexia, weight loss, 
and hepatosplenomegaly. As in our patient, these clin-
ical presentations usually mimic infection with multi- 
organ failure, and make early diagnosis difficult. The 
disease course was usually aggressive. Bone marrow 
examination is mandatory to make the diagnosis of 
primary LBCL, and should be performed early in pa-
tients with unexplained fever, hepatosplenomegaly, 
jaundice, and cytopenia. 
HLH, also called as hemophagocytic syndrome , is 
a life-threating syndrome characterized by fever, cy-
topenia, hepatosplenomegaly, and hyperbilirubinemia 
[10]. According to the HLH-2004 diagnostic and 
therapeutic guidelines, the diagnosis of HLH can be 
made with either molecular diagnosis or diagnostic 
clinical criteria, including fever, splenomegaly, cyto-
penia, hypertriglyceridemia and/or hypofibrinogemia, 
hemophagocytosis, ferritin level, soluble CD25 level, 
and NK-cell activity [11]. In adults, HLH is mostly 
secondary, and may be related to infection of various 
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 pathogens, autoimmune diseases, and malignancies. 
Hematological malignancies, especially lymphomas, 
accounted for 22 to 57% of adult HLH in the reported 
case series [12,13]. HLH could be observed in 35% 
(13/37) and 63% (7/11) of patients with primary bone 
marrow LBCL in the series of Kajiura et al. [9] and 
Yeh et al. [2], respectively. However, HLH was not 
observed in another series using similar inclusion cri-
teria [6]. The exact prevalence of HLH in primary 
bone marrow LBCL remains unclear. 
In our case, the phenotype of LBCL can be deter-
mined as non-GC type by immunohistochemical 
staining using the decision tree proposed by Hans et al. 
[14]. It is compatible with the finding that most 
LBCLs involving bone marrow, liver, and spleen are 
of the non-GC phenotype. Positivity of CD5 in LBCL 
had been found to be a poor prognostic factor [15]. 
The successful treatment in our patient also supported 
this finding in addition to the cause of early diagnosis. 
Most cases of primary bone marrow LBCL are also 
negative on CD5 [2,3,6,8].  
Patients with the Asian variant of intravascular 
LBCL may also present with hepatosplenomegaly, 
bone marrow involvement, pancytopenia, and HLH 
[1]. Although they share common clinical features 
with primary bone marrow LBCL, these diseases can 
be differentiated by the presence of intravascular pro-
liferation of lymphoma under pathological study [2].  
Since primary bone marrow LBCL is rare, there is 
no standard treatment to date. Most patients were 
treated with anti-lymphoma chemotherapy in combi-
nation with rituximab [2,6]. A large proportion of pa-
tients have been managed with supportive care only, 
mainly due to their poor general condition at the time 
of diagnosis. The prognosis of patients with primary 
bone marrow LBCL was usually poorer than those 
with systemic diffuse LBCL with bone marrow in-
volvement [2]. In our case, the patient was success-
fully treated with R-COP chemotherapy. Considering 
her advanced age, hematopoietic stem cell transplan-
tation (HSCT) was not planned. Patients successfully 
treated with allogeneic and autologous HSCT had 
been reported in the literature [2,6]. Contamination of 
autograft by lymphoma cells was a concern in patients 
with primary bone marrow LBCL. A recent case re-
port from Japan had demonstrated a case of primary 
bone marrow LBCL treated successfully with high 
dose chemotherapy and rescued by in vivo rituxi-
mab-purged autologous stem cells [5]. Further studies 
are needed to investigate the role of HSCT in primary 
bone marrow LBCL. 
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